Tags

Type your tag names separated by a space and hit enter

Foenumoside B isolated from Lysimachia foenum-graecum extract suppresses LPS-induced inflammatory response via NF-κB/AP-1 inactivation in murine macrophages and in endotoxin-induced shock model.
Eur J Pharmacol 2018; 832:120-128EJ

Abstract

Foenumoside B (FSB), a bioactive component isolated from the Lysimachia foenum-graecum extract (LFE), has been shown to possess anti-inflammatory effects, but the underlying molecular mechanisms involved have not been elucidated. Accordingly, the authors investigated the mechanisms responsible for the anti-inflammatory effects of FSB in murine macrophages activated by LPS. FSB suppressed the LPS-induced expressions of iNOS and COX-2 at protein and mRNA levels and consequently decreased NO and PGE2 production in RAW264.7 and primary macrophages. FSB also reduced the LPS-induced inductions of TNF-α, IL-6 and IL-1β at protein and mRNA levels. Studies of the molecular mechanisms involved in the anti-inflammatory effects of FSB showed that it inhibited the transcriptional activities of NF-κB and AP-1, and the nuclear translocation of NF-κB via inhibition of the phosphorylations of AKT, p38 and STAT3. In a sepsis model, pretreatment with FSB inhibited the LPS-stimulated mRNA and protein levels of proinflammatory mediators, such as, iNOS, COX-2, TNF-α, IL-6 and IL-1β in plasma and liver. Importantly, FSB increased the survival rate of mice in the LPS-induced sepsis model. Taken together, these results show that the anti-inflammatory effects of FSB against LPS-induced inflammatory conditions are associated with inhibitions of the phosphorylations of AKT, p38 and STAT3 followed by the transcriptional suppressions of NF-κB and AP-1, and thus, reduced expressions of pro-inflammatory genes.

Authors+Show Affiliations

Department of Pharmacology, Gachon University School of Medicine, Incheon 21999, Republic of Korea.Department of Pharmacology, Gachon University School of Medicine, Incheon 21999, Republic of Korea.Natural Substance Research Team, Pharmaceutical R&D center, Kolmar Korea Co. Ltd, Sejong 30004, Republic of Korea.Department of Pharmacology, Gachon University School of Medicine, Incheon 21999, Republic of Korea; Gachon Medical Research Institute, Gil Medical Center, Incheon 21565, Republic of Korea. Electronic address: hgcheon@gachon.ac.kr.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29782861

Citation

Choi, Hye-Eun, et al. "Foenumoside B Isolated From Lysimachia Foenum-graecum Extract Suppresses LPS-induced Inflammatory Response Via NF-κB/AP-1 Inactivation in Murine Macrophages and in Endotoxin-induced Shock Model." European Journal of Pharmacology, vol. 832, 2018, pp. 120-128.
Choi HE, Kwak HJ, Kim SK, et al. Foenumoside B isolated from Lysimachia foenum-graecum extract suppresses LPS-induced inflammatory response via NF-κB/AP-1 inactivation in murine macrophages and in endotoxin-induced shock model. Eur J Pharmacol. 2018;832:120-128.
Choi, H. E., Kwak, H. J., Kim, S. K., & Cheon, H. G. (2018). Foenumoside B isolated from Lysimachia foenum-graecum extract suppresses LPS-induced inflammatory response via NF-κB/AP-1 inactivation in murine macrophages and in endotoxin-induced shock model. European Journal of Pharmacology, 832, pp. 120-128. doi:10.1016/j.ejphar.2018.05.022.
Choi HE, et al. Foenumoside B Isolated From Lysimachia Foenum-graecum Extract Suppresses LPS-induced Inflammatory Response Via NF-κB/AP-1 Inactivation in Murine Macrophages and in Endotoxin-induced Shock Model. Eur J Pharmacol. 2018 Aug 5;832:120-128. PubMed PMID: 29782861.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Foenumoside B isolated from Lysimachia foenum-graecum extract suppresses LPS-induced inflammatory response via NF-κB/AP-1 inactivation in murine macrophages and in endotoxin-induced shock model. AU - Choi,Hye-Eun, AU - Kwak,Hyun Jeong, AU - Kim,Seul Ki, AU - Cheon,Hyae Gyeong, Y1 - 2018/05/18/ PY - 2018/01/17/received PY - 2018/05/17/revised PY - 2018/05/17/accepted PY - 2018/5/22/pubmed PY - 2018/10/9/medline PY - 2018/5/22/entrez KW - AP-1 KW - FSB KW - Inflammation KW - LPS KW - Macrophage KW - NF-κB KW - Sepsis SP - 120 EP - 128 JF - European journal of pharmacology JO - Eur. J. Pharmacol. VL - 832 N2 - Foenumoside B (FSB), a bioactive component isolated from the Lysimachia foenum-graecum extract (LFE), has been shown to possess anti-inflammatory effects, but the underlying molecular mechanisms involved have not been elucidated. Accordingly, the authors investigated the mechanisms responsible for the anti-inflammatory effects of FSB in murine macrophages activated by LPS. FSB suppressed the LPS-induced expressions of iNOS and COX-2 at protein and mRNA levels and consequently decreased NO and PGE2 production in RAW264.7 and primary macrophages. FSB also reduced the LPS-induced inductions of TNF-α, IL-6 and IL-1β at protein and mRNA levels. Studies of the molecular mechanisms involved in the anti-inflammatory effects of FSB showed that it inhibited the transcriptional activities of NF-κB and AP-1, and the nuclear translocation of NF-κB via inhibition of the phosphorylations of AKT, p38 and STAT3. In a sepsis model, pretreatment with FSB inhibited the LPS-stimulated mRNA and protein levels of proinflammatory mediators, such as, iNOS, COX-2, TNF-α, IL-6 and IL-1β in plasma and liver. Importantly, FSB increased the survival rate of mice in the LPS-induced sepsis model. Taken together, these results show that the anti-inflammatory effects of FSB against LPS-induced inflammatory conditions are associated with inhibitions of the phosphorylations of AKT, p38 and STAT3 followed by the transcriptional suppressions of NF-κB and AP-1, and thus, reduced expressions of pro-inflammatory genes. SN - 1879-0712 UR - https://www.unboundmedicine.com/medline/citation/29782861/Foenumoside_B_isolated_from_Lysimachia_foenum_graecum_extract_suppresses_LPS_induced_inflammatory_response_via_NF_κB/AP_1_inactivation_in_murine_macrophages_and_in_endotoxin_induced_shock_model_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(18)30287-5 DB - PRIME DP - Unbound Medicine ER -